Green light for reliance on Article 57 database for key pharmacovigilance information on medicines for human use in Europe
As of 1 February 2016, for both centrally and nationally authorised medicines, companies will no longer be required to submit type IA variations in relation to the Qualified Person Responsible for Pharmacovigilance and Pharmacovigilance System Master File.
At its December 2015 meeting, the European Medicines Agency’s (EMA) Management Board confirmed that the Article 57 database of medicines authorised in the European Union (EU) can now be relied upon to provide the name and contact details of the Qualified Person Responsible for Pharmacovigilance (QPPV) for each authorised medicine in the EU and the location where the Pharmacovigilance System Master File (PSMF) of the marketing-authorisation holder of a given medicine is held.
This endorsement by the Board allows EMA and the national competent authorities in the EU to fully rely on the Article 57 database for this information. This allows all EU regulators to access this information at a single point facilitating their work and helping to coordinate enquiries from regulators to companies and the conduct of pharmacovigilance inspections.
As a result of reliance on the Article 57 database, for medicines for human use companies will no longer be required to submit type IA variations to notify regulators of changes in relation to the contact details of their QPPV or the location of their PSMF, simplifying processes for the notification of these changes for both companies and regulators.
The simplification will apply from 1 February 2016. From that date, type IA variations for QPPV and PSMF location no longer need to be submitted. In line with legal requirements, the Article 57 database will need to continue to be kept up to date with any changes to products authorised for human use.
The Article 57 database is a repository of structured and quality-assured information on all medicines for human use that are authorised in the European Economic Area (EEA), whether they are centrally or nationally authorised. EMA established the database in 2012 and it currently contains approximately 500,000 medicines.
The information contained in the database is provided by marketing authorisation holders, based on the legal obligation set out in Article 57 of Regulation 726/2004/EU. The quality of the data is continuously verified by EMA according to a robust quality assurance and control process, established together with the industry.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance